Eli Lilly (LLY) director buys 215 shares at $1,021 each
Eli Lilly & Co (LLY) director Katherine Baicker reported a new stock purchase.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eli Lilly & Co (LLY) director Katherine Baicker reported a new stock purchase. On 11/17/2025, she acquired 215.327 shares of Eli Lilly common stock at a price of $1,021.7 per share. Following this transaction, she directly beneficially owns 23,502.628 shares of Eli Lilly common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 215.327 | $1,021.70 | $220K |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What type of SEC filing did Eli Lilly (LLY) submit in this document?
This document is a Form 4, which reports changes in the beneficial ownership of Eli Lilly & Co (LLY) securities by an insider.
Who reported a transaction in Eli Lilly (LLY) stock on this Form 4?
Katherine Baicker, identified as a director of Eli Lilly & Co, is the reporting person for the transaction disclosed.
When did the reported Eli Lilly (LLY) insider transaction occur?
The insider transaction took place on 11/17/2025, as reported in the Form 4.
AI-generated analysis. How Rhea-AI works. Not financial advice.